Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic

Daptomycin has a Rapidly Bactericidal Mode of Action The launch of
daptomycin for the treatment of both methicillin-sensitive and resistant
Staphylococcus aureus (MSSA and MRSA) bloodstream infections (bacteraemia) and
heart infections (right-sided infective endocarditis) has been announced today
by Novartis Pharmaceuticals UK Ltd.(1) Daptomycin, one of only two new classes
of antibiotic in over 20 years, has been shown to be as effective as existing
agents in treating a range of serious Gram-positive infections, offering an
important new option for healthcare professionals. MRSA is a frequent cause of
bacteraemia and is associated with serious complications, including
endocarditis (in 30-40% of cases) and has a high mortality rate.(2) Over 7,000
people each year contract bacteraemia and the incidence is rising.(3) From 1993
to 2005 the number of deaths increased from 51 to 1,629.(4) There is evidence
that some strains of MRSA are developing resistance to existing antibiotic
options.(5) Daptomycin, which is rapidly bactericidal, has a specific mode of
action, which reduces the likelihood of resistance developing. Daptomycin’s
once daily dosing and tolerability profile, with no need for therapeutic drug
monitoring, has the potential to simplify the management of patients with
complicated infections. Daptomycin is already approved for the treatment of
complicated skin and soft tissue infections (cSSTI) caused by Staphylococcus
aureus and other Gram positive bacteria, including MRSA. (1) Clinical trials in
cSSTI showed daptomycin had a faster time to cure (63% of patients successfully
treated with daptomycin achieved a clinical cure within four to seven days
versus 33% with comparators such as vancomyin and anti-staphylococcal
Daptomycin is an antibiotic with a distinct mode of action which has
several notable features, including once-daily dosing and no requirement
for serum drug monitoring, which may reduce the burden on healthcare
professionals and hospitalisation costs.